PIK3CA and colorectal carcinoma: A total of 26.7% of these CRC patients have mutations in the PI3K/AKT/MTOR pathway (PIK3CA 18%, PTEN 2.8%, PIK3CG 2.5%, PIK3R1 2.4% and AKT1 1%) [5].